MarketCap
ANI Pharmaceuticals ANIP
$ 76.54
2.37%
Facebook
X
Telegram
ANI Pharmaceuticals Financial Ratios 2025-2008 | ANIP
Brief overview of ANI Pharmaceuticals's valuation and returns
The review covers five available annual periods spanning 2016 to 2025.
Market valuation is represented by P/E 15.92x (median 63.5x), EV/EBITDA 9.16x (median 27.91x), P/S 1.41x (median 2.21x). On average, this basket is 64.1% below its own five-year medians. The market values the business at a discount to recent history.
The 1/P/E calculation produces a 6.3% earnings yield. It does not capture future growth or capital structure.
Current measures of operating quality are ROE 14.4%, ROA 5.4%, ROCE 20.5%. Quality ratios send a mostly positive signal: resources are productive, with room for improvement.
PEG is 0.15x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.
The time from paying for inputs to receiving cash fell from 385.8 days to 195.6 days. Cash turnover improved.
What the ratios show
ANI Pharmaceuticals's high-quality returns come with historically restrained multiples. Price appears more cautious than current business efficiency.
Annual Financial Ratios ANI Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
15.9 | -62.9 | 63.5 | -14.6 | -12.0 | -15.1 | 119.0 | 40.9 | -724.0 | 169.4 | 23.7 | 21.3 | 355.8 | -1.1 | -1.2 | -16.4 | -9.3 | - |
P/S |
1.4 | 1.9 | 2.5 | 2.2 | 2.4 | 1.6 | 3.5 | 3.1 | 4.4 | 5.2 | 4.8 | 10.9 | 3.6 | 13.7 | 147.0 | 306.9 | 353.0 | - |
EPS |
3.5 | -1.0 | 0.9 | -3.0 | -3.4 | -1.9 | 0.5 | 1.3 | -0.1 | 0.3 | 1.3 | 2.6 | -0.9 | -1.3 | -3.1 | -4.2 | -8.4 | - |
EV (Enterprise Value) |
1.86 B | 1.91 B | 1.43 B | 1.07 B | 822 M | 599 M | 907 M | 824 M | 985 M | 792 M | 334 M | 567 M | 99.5 M | 42.1 M | 31.3 M | 747 M | 414 M | -11.8 M |
EBITDA per Share |
10.1 | 3.54 | 5.93 | 1.33 | 0.59 | 2.39 | 5.15 | 5.92 | 4.95 | 4.29 | 3.48 | 2.18 | 0.396 | -6.32 | -18.6 | -1.18 | 0.02 | - |
EV/EBITDA |
9.2 | 27.9 | 13.4 | 49.5 | 109.5 | 17.9 | 13.9 | 11.2 | 16.6 | 15.5 | 8.1 | 23.2 | 47.8 | -0.2 | -0.5 | -57.4 | 3017.4 | - |
PEG |
0.15 | -1.04 | 0.96 | -23.33 | 0.56 | 9.0 | -1.95 | 0.03 | 5.74 | -2.28 | -0.49 | 0.06 | 4.05 | -0.02 | -0.05 | - | - | - |
P/B |
2.3 | 2.8 | 2.6 | 2.1 | 1.4 | 1.7 | 3.4 | 3.2 | 4.5 | 3.9 | 2.3 | 4.4 | 2.6 | 1.1 | 1.7 | 39.7 | - | - |
P/CF |
6.7 | 18.7 | 10.1 | -22.4 | 153.3 | 22.4 | 40.1 | 11.3 | -11.4 | -5.5 | -23.6 | -44.6 | -18.9 | -1.2 | -1.3 | - | - | - |
ROE % |
14.43 | -4.71 | 4.39 | -15.30 | -12.76 | -11.52 | 2.86 | 7.85 | -0.62 | 2.32 | 9.60 | 20.57 | 0.73 | -98.38 | -136.48 | -241.27 | -300.23 | - |
ROA % |
5.42 | -1.48 | 2.10 | -6.32 | -5.52 | -4.89 | 1.33 | 3.60 | -0.26 | 1.22 | 5.39 | 10.90 | 0.68 | -71.49 | -82.73 | -103.19 | - | - |
ROCE % |
20.55 | 0.14 | 10.85 | -11.25 | -11.92 | -8.18 | 4.16 | 13.34 | 7.84 | 9.20 | 11.96 | 7.99 | 2.19 | -82.24 | -92.34 | -68.77 | - | - |
Current Ratio |
1.6 | 1.5 | 2.0 | 1.8 | 1.9 | 1.7 | 3.0 | 0.9 | 3.4 | 3.2 | 16.4 | 15.4 | 7.8 | 3.3 | 8.0 | 1.7 | - | - |
DSO |
103.9 | 114.0 | 122.8 | 169.6 | 189.4 | 147.0 | 127.5 | 117.4 | 121.3 | 130.2 | 104.9 | 112.8 | 151.8 | - | - | - | - | - |
DIO |
149.6 | 180.9 | 217.7 | 246.0 | 258.5 | 228.2 | 278.4 | 202.4 | 174.2 | 195.9 | 385.0 | 239.2 | 128.7 | - | - | - | - | - |
DPO |
57.9 | 60.1 | 66.3 | 68.7 | 62.1 | 54.2 | 84.4 | 44.4 | 16.8 | 25.4 | 59.4 | 84.4 | 52.3 | - | 22999.9 | - | - | - |
Operating Cycle |
253.5 | 294.9 | 340.5 | 415.5 | 447.9 | 375.2 | 405.8 | 319.9 | 295.6 | 326.2 | 489.9 | 352.0 | 280.6 | - | - | - | - | - |
Cash Conversion Cycle |
195.6 | 234.8 | 274.2 | 346.8 | 385.8 | 321.0 | 321.4 | 275.5 | 278.8 | 300.8 | 430.5 | 267.5 | 228.3 | - | -22999.9 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios ANI Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.09 | 1.31 | 1.19 | 0.37 | 0.7 | -1.27 | -0.14 | 0.84 | 0.46 | 0.3 | 0.06 | - | -0.55 | -0.94 | -1.27 | - | -0.37 | -1.17 | 0.01 | -0.3 | 0.04 | -1.03 | -0.59 | -0.41 | 0.32 | 0.55 | 0.04 | 0.46 | 0.43 | 0.24 | 0.19 | -0.83 | 0.41 | 0.23 | 0.1 | -0.09 | 0.22 | 0.1 | 0.12 | 0.25 | 0.4 | 0.31 | 0.38 | 1.85 | 0.59 | -0.21 | 0.33 | - | 0.13 | -6.03 | - | -0.16 | -1295.1 | -1644.86 | -0.53 | -0.36 | -0.73 | -0.16 | -0.2 |
EBITDA per Share |
2.84 | 2.86 | 2.93 | 1.87 | 2.5 | -0.25 | 1.03 | 1.83 | 1.76 | 1.53 | 1.5 | - | 0.56 | 0.05 | -0.29 | - | 0.64 | -0.35 | 1.16 | - | 1.18 | -0.01 | 0.28 | - | 1.41 | 1.58 | 1.75 | - | 1.59 | 1.33 | 1.27 | - | 1.42 | 1.22 | 0.98 | - | 1.21 | 0.98 | 0.9 | - | 0.92 | 0.87 | 0.96 | - | 0.84 | -0.16 | 0.42 | - | 0.13 | -3.15 | - | - | - | 0.04 | -0.06 | - | -0.75 | -0.83 | -0.19 |
ROE % |
16.60 | 16.21 | 5.01 | -0.75 | -0.40 | -2.62 | 3.79 | 4.29 | 1.54 | -5.56 | -13.35 | -13.81 | -16.13 | -20.72 | -15.90 | -9.63 | -11.49 | -8.94 | -7.90 | -11.52 | -11.94 | -10.33 | -0.93 | 2.86 | 7.69 | 7.27 | 5.31 | 5.10 | 7.80 | 6.78 | 6.03 | 4.89 | 6.39 | 4.36 | 3.61 | 2.96 | 5.80 | 6.54 | 8.60 | 7.81 | 12.63 | 8.10 | 8.27 | 5.54 | 8.45 | -7.57 | -5.24 | -7.65 | 1.69 | -0.34 | 10.77 | -26.30 | -16.24 | -50.79 | -90.31 | -99.50 | -33.67 | -39.60 | -45.62 |
ROA % |
6.25 | 5.81 | 1.86 | -0.28 | 0.20 | -0.28 | 1.78 | 2.03 | 0.87 | -2.23 | -5.66 | -5.85 | -6.80 | -8.57 | -6.57 | -3.86 | -4.65 | -3.61 | -3.35 | -4.89 | -5.16 | -4.40 | -0.28 | 1.33 | 3.56 | 3.35 | 2.44 | 2.34 | 3.48 | 2.96 | 2.60 | 2.08 | 2.86 | 2.07 | 1.83 | 1.55 | 3.15 | 3.62 | 4.80 | 4.38 | 6.94 | 4.45 | 4.47 | 2.94 | 5.61 | -7.24 | -5.76 | -7.04 | -36.04 | -41.46 | -30.91 | -57.97 | -39.62 | -57.29 | -81.55 | -82.73 | -20.41 | -24.01 | -27.65 |
ROCE % |
24.04 | 23.52 | 11.55 | 5.52 | 6.51 | 3.28 | 11.48 | 10.35 | 8.75 | 0.43 | -8.57 | -11.71 | -13.58 | -20.08 | -14.45 | -8.47 | -8.30 | -5.01 | -2.68 | -8.18 | -10.55 | -8.54 | 1.61 | 7.68 | 15.68 | 17.36 | 16.68 | 17.92 | 16.35 | 16.56 | 16.88 | 16.21 | 12.75 | 12.08 | 11.14 | 11.84 | 14.99 | 15.60 | 17.79 | 20.43 | 24.22 | 24.80 | 17.79 | 14.31 | 8.58 | -6.50 | -3.75 | -6.25 | 2.26 | 0.76 | 8.61 | -16.98 | -1.16 | -36.10 | -69.28 | -88.16 | -34.45 | -34.55 | -43.48 |
Current Ratio |
1.7 | 1.6 | 1.6 | 1.5 | 1.5 | 1.5 | 2.1 | - | 2.0 | 2.0 | 1.8 | 1.8 | 1.8 | 1.8 | 1.9 | 1.9 | 1.7 | 1.7 | 1.8 | 1.7 | 1.7 | 1.7 | 1.7 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.7 | 1.7 | 1.7 | 1.7 | 2.1 | 2.1 | 2.1 | 2.1 | 2.3 | 2.3 | 2.3 | 2.3 | 2.2 | 2.1 | 2.1 | 2.1 | 12.6 | - | - | 4.8 | 1.3 | 1.3 | 0.8 | 2.3 | 2.5 | 2.5 | 2.5 | 2.5 |
DSO |
90.9 | 97.6 | 95.8 | 96.3 | 96.5 | 111.5 | 54.9 | 59.4 | 121.7 | 136.1 | 145.3 | - | 158.3 | 174.2 | 184.1 | - | 174.7 | 173.1 | 157.1 | 152.7 | 165.0 | 180.3 | 153.9 | 137.2 | 128.2 | 121.1 | 118.2 | 103.6 | 116.7 | 125.2 | 121.3 | 113.5 | 111.4 | 119.8 | 130.4 | 109.6 | 108.7 | 133.6 | 150.6 | 111.0 | 100.2 | 102.5 | 95.2 | 75.0 | 90.8 | 237.4 | 124.8 | - | 145.7 | 185.6 | 147.2 | 251.9 | 98.4 | 47.8 | - | - | - | - | - |
DIO |
130.6 | 141.4 | 139.1 | 168.6 | 178.3 | 197.8 | 99.2 | 98.9 | 200.1 | 224.4 | 252.9 | - | 261.4 | 227.1 | 219.5 | - | 241.7 | 260.8 | 275.6 | - | 275.8 | 268.1 | 228.0 | - | 292.9 | 281.1 | 274.7 | - | 236.8 | 222.7 | 172.5 | - | 163.3 | 163.0 | 177.9 | - | 143.3 | 202.6 | 529.4 | - | 374.7 | 388.9 | 346.7 | - | 224.1 | 324.1 | 192.0 | - | 118.5 | 147.9 | 119.9 | - | 110.4 | 60.5 | - | - | - | - | - |
DPO |
65.4 | 68.0 | 60.8 | 65.8 | 71.2 | 79.3 | 38.5 | 31.6 | 59.4 | 66.0 | 75.0 | - | 64.7 | 64.2 | 59.9 | - | 45.8 | 54.7 | 57.1 | - | 51.1 | 49.6 | 54.1 | - | 88.8 | 85.3 | 72.8 | - | 52.0 | 48.9 | 27.6 | - | 15.7 | 15.7 | 19.5 | - | 18.6 | 26.2 | 73.0 | - | 57.8 | 60.0 | 78.3 | - | 79.1 | 114.4 | 71.0 | - | 48.1 | 60.1 | 64.9 | - | 78.3 | 67.2 | - | - | - | - | - |
Operating Cycle |
- | - | 234.9 | 264.9 | 274.8 | 309.3 | - | - | 321.8 | 360.5 | 398.2 | - | 419.7 | 401.4 | 403.6 | - | 416.4 | 434.0 | 432.7 | 152.7 | 440.8 | 448.4 | 381.9 | 137.2 | 421.2 | 402.2 | 392.9 | 103.6 | 353.5 | 347.9 | 293.8 | 113.5 | 274.7 | 282.8 | 308.4 | 109.6 | 252.0 | 336.2 | 680.0 | 111.0 | 474.9 | 491.5 | 441.9 | 75.0 | 314.9 | 561.5 | 316.8 | - | 264.2 | 333.5 | 267.1 | 251.9 | 208.9 | 108.3 | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 174.2 | 199.1 | 203.6 | 230.1 | - | - | 262.4 | 294.5 | 323.2 | - | 355.0 | 337.1 | 343.6 | - | 370.6 | 379.3 | 375.5 | 152.7 | 389.7 | 398.8 | 327.8 | 137.2 | 332.3 | 317.0 | 320.1 | 103.6 | 301.6 | 299.1 | 266.2 | 113.5 | 259.0 | 267.1 | 288.8 | 109.6 | 233.5 | 310.0 | 607.0 | 111.0 | 417.1 | 431.4 | 363.6 | 75.0 | 235.8 | 447.1 | 245.8 | - | 216.1 | 273.4 | 202.2 | 251.9 | 130.5 | 41.1 | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company ANI Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
